Original Paper

Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1†

  1. Yukiko Shibahara1,
  2. Yasuhiro Miki1,
  3. Yoshiaki Onodera1,
  4. Shuko Hata1,
  5. Monica SM Chan1,2,3,4,
  6. Christopher CP Yiu1,3,
  7. Tjing Y Loo1,2,3,4,
  8. Yasuhiro Nakamura1,
  9. Jun-ichi Akahira1,
  10. Takanori Ishida5,
  11. Keiko Abe1,
  12. Hisashi Hirakawa6,
  13. Louis WC Chow2,3,4,7,
  14. Takashi Suzuki1,
  15. Noriaki Ouchi5,
  16. Hironobu Sasano1,*

Article first published online: 30 APR 2012

DOI: 10.1002/path.4019

Issue

The Journal of Pathology

The Journal of Pathology

Volume 227, Issue 3, pages 357–366, July 2012

Additional Information

How to Cite

Shibahara, Y., Miki, Y., Onodera, Y., Hata, S., Chan, M. S., Yiu, C. C., Loo, T. Y., Nakamura, Y., Akahira, J.-i., Ishida, T., Abe, K., Hirakawa, H., Chow, L. W., Suzuki, T., Ouchi, N. and Sasano, H. (2012), Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1. J. Pathol., 227: 357–366. doi: 10.1002/path.4019

Author Information

  1. 1

    Department of Pathology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan

  2. 2

    UNIMED Medical Institute, Comprehensive Centre for Breast Diseases, 10/F, Luk Kwok Centre, 72 Gloucester Road, Wanchai, Hong Kong

  3. 3

    Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong

  4. 4

    Clinical Trial Centre, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong

  5. 5

    Department of Surgery, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan

  6. 6

    Department of Surgery, Tohoku Kosai Hospital, 2-3-11 Kokubun-cho, Aoba-ku, Sendai, Miyagi 980-0803, Japan

  7. 7

    Organisation of Oncology and Translational Research, Unit A, 9/F, CNT Commercial Building, 302 Queen's Road Central, Hong Kong

*Department of Pathology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan.

  1. †

    Conflict of interest statement: HS received educational research grants from Novartis Japan Oncology and Pfizer Japan Oncology. YM received educational research grants from Pfizer Japan. The other authors disclosed no potential conflicts of interest.

Publication History

  1. Issue published online: 6 JUN 2012
  2. Article first published online: 30 APR 2012
  3. Accepted manuscript online: 9 MAR 2012 10:02AM EST
  4. Manuscript Accepted: 21 FEB 2012
  5. Manuscript Revised: 7 FEB 2012
  6. Manuscript Received: 24 OCT 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (2468K)

Options for accessing this content:

  • If you have access to this content through a society membership, please first log in to your society website.
  • If you would like institutional access to this content, please recommend the title to your librarian.
  • Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
  • You can purchase online access to this Article for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

If your institution is a registered Wiley Online Library customer, you can log in under your institution's name to see our content. This access is provided by Shibboleth or Athens.

Type your institution's name in the box below. If your institution is a Wiley customer, it will appear in the list of suggested institutions.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >

View Full Article with Supporting Information (HTML) Get PDF (2468K)